

1800 Alta Vista Drive Ottawa ON K1G 4J5 Canada

**ACTION REQUIRED** 

Cutaquig<sup>®</sup> 4g Inventory Customer Letter # 2020-33

2020-07-14

Dear Colleagues:

During last summer's subcutaneous immunoglobulin (SCIg) shortage, Canadian Blood Services procured additional Cutaquig® to relieve the pressure on Cuvitru®. Some of that inventory was short-dated with an expiry of April 30, 2021. With current demand rates, there is an excess inventory of Cutaquig® 4g vials which will be wasted if no action is taken.

In an effort to avoid wasting product, we are asking that all requests for 8g vials of Cutaquig® be replaced with two of the 4g vials where clinically appropriate. Access to 8g vials of Cutaquig® should be restricted to those patients who are unable to manage multiple 4g vials such as those with dexterity limitations. If you are unsure, please confirm with the treating hospital medical team.

Canadian Blood Services will automatically substitute orders for 8g vials of Cutaquig® with the 4g vials. If you require Cutaquig® 8g vials for specific patients that are unable to manage 4g vials, please clearly indicate in the comments section on the Volume Expanders / Immune Globulins and S/D Plasma order form not to substitute with the 4g vials. This measure will be in place until the current stock of Cutaquig® 4g vials is depleted which is anticipated to take 6 to 7 months.

Hospital transfusion medicine services may see some new patients started on Cutaquig® over the next few months as Canadian Blood Services works with prescribers to avoid wastage. Importantly, this does not signify a SCIg shortage, and the primary SCIg remains Cuvitru®.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at <u>www.blood.ca</u> in the "Hospitals Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Sylvain Grenier Director, Plasma Related Products Formulary Program